Olivier Danos | Chief Scientific Officer
Regenxbio Inc

Olivier Danos, Chief Scientific Officer, Regenxbio Inc

Dr. Olivier Danos, Ph.D. has been Chief Scientific Officer of Regenxbio Inc. since March 2017. Dr. Danos serves as the Senior Scientific Advisor of the entire SAF-301 program. He served as Senior Vice President of Cell & Gene Therapy at Biogen Inc. until March 2017 and served as its Senior Vice President of Gene Therapy since September 2014. Dr. Danos Co-founded Lysogene S.A. in 2009 and served as its Scientific Advisor and Executive Director. From 2011 to 2014, he served as the Senior Vice President of Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals (New-York, USA). In this role, he was instrumental in assembling a gene therapy program and a technology platform for the development of controllable gene expression systems. From 2008 to 2011, he served as the Director of the Gene Therapy Consortium of University College of London (UK) where he implemented a GMP AAV facility. He simultaneously led a Gene Therapy Research Team at the Necker Hospital - Enfants Malades in Paris. He served as Senior Director of Research at Somatix Therapy Corporation. From 1997 to 2006, he served as the Chief Scientific Officer of Genethon, a leading GMP laboratory dedicated to the development of gene and cellular therapies for genetic diseases and funded by the not-for-profit organization Association Française contre les Myopathies, as well as the Director of a CNRS (National Centre for Scientific Research) Research Unit associated with the laboratory. Dr. Danos serves as Director at Lysogene S.A. He has been Member of Scientific Advisory Board at TxCell S.A. since August 24, 2016. He has been a Member of Clinical and Scientific Advisory Board at Alcyone Lifesciences, Inc. since July 07, 2015. His other previous appointments include Scientific Director of Généthon and Senior Research Director with the CNRS in France. He has held several senior roles at the French National Centre for Scientific Research (CNRS) and at the Institut Pasteur in Paris. Dr. Danos is the former president and a founding member of the European Society of Gene and Cell Therapy. Dr. Danos holds Master's in Genetics and Molecular Biology at University of Paris Orsay and his Ph.D. in Biology at the Pasteur Institute and University of Paris Diderot.


World Orphan Drug Congress USA 2018 - Conference Day One @ 15:40

Creating value in gene therapy clinical development programs, achieving trial optimization and supporting the path to commercialization

  • Investigating novel vector technologies that can improve efficacy while reducing immunogenicity and potential re-dosing 
  • Thinking about end to end clinical development including trial design, enrollment, execution, supply chain and manufacturing 
  • How can clinical development be optimized to support scalability? What are the current limitations faced by this field despite a decade of improvements?

back to speakers